on behalf of GETH (Grupo Español de Trasplante Hematopoy etico) and PETHEMA (Programa Español de Tratamiento en Hematolog ıa), Spanish Society of Hematology Adults with high-risk acute lymphoblastic leukemia (HR-ALL) have a poor outcome with standard chemotherapy and usually undergo unrelated stem cell transplantation (SCT) if a matched sibling donor is not available. We analyzed the outcome of adult patients with unrelated SCT for HR-ALL and studied the possible effect of the hematopoietic stem cell source of the transplant. A total of 149 adult patients (median age, 29 years, range, 15-59 years) with HR-ALL underwent unrelated SCT in 13 Spanish institutions between 2000 and 2007. Patients in first complete remission (CR1) at transplantation had at least one adverse prognostic factor (advanced age, adverse cytogenetics, hyperleukocytosis, or slow response to induction therapy). ALL was in CR1 in 81 patients (54%), in second CR (CR2) in 37 patients (25%), in third CR (CR3) in 11 patients (7%), and with overt disease in 20 patients (13%). The hematopoietic source was unrelated cord blood (UCB) in 62 patients and an unrelated donor (UD) in 87 patients. The patients undergoing UCB-SCT and UD-SCTwere comparable in terms of the main clinical and biological features of ALL, except for a higher frequency of patients with more overt disease in the UCB-SCT group. There was no statistically significant difference in overall survival (OS) or disease-free survival (DFS) at 5 years between the 2 groups. Treatment-related mortality (TRM) was significantly lower in the UCB-SCT group (P 5.021). The probability of relapse at 1 year was 17% (95% confidence interval [CI], 7%-27%) for the UD-SCT group and 27% (95% CI, 14%-40%) for the UCB-SCT group (P 5.088), respectively. Only disease status at transplantation (CR1, 41% [95% CI, 18%-64%] vs CR2, 51% [95% CI, 17%-85%] vs advanced disease, 66% [95% CI, 46%-86%]; P 5.001) and the absence of chronic graft-versus-host disease (74% [95% CI, 46%-100%] vs 33% [95% CI, 17%-49%]; P 5 .034) were significant factors for relapse. All unrelated transplantation modalities were associated with high treatment-related mortality for adult HR-ALL patients without a sibling donor. UCB-SCT and UD-SCT were found to be equivalent options. Disease status at transplantation and chronic GVHD were the main factors influencing relapse in both transplantation modalities.
INTRODUCTION
Adults with acute lymphoblastic leukemia (ALL) with high-risk features at diagnosis, recurrent disease, or slow response have a poor outcome with standard chemotherapy. Autologous stem cell transplantation (SCT) has not proved to provide any advantage for ALL patients in complete remission (CR), because of a high frequency of relapse [1, 2] . Despite a high frequency of treatment-related mortality (TRM), allogeneic SCT remains the best therapeutic option in high-risk ALL [3] [4] [5] [6] [7] [8] . High-risk adult ALL patients have a very poor outcome, with an expected diseasefree survival (DFS) of only 35%-45% in many trials [9, 10] . Consequently, in most transplantation centers, these patients are considered for alternativedonor SCT when a matched sibling donor is not available [11] [12] [13] [14] . The alternative hematopoietic source can be a nonidentical relative, an unrelated donor (UD), or unrelated cord blood (UCB) units [15] [16] [17] [18] [19] [20] [21] [22] .
Long-term results of UD-SCT in adult patients are scarce, and the best unrelated progenitor source remains unclear. To date, no comparative study on the outcomes of adult ALL patients in Western countries who underwent UD-SCT based on the stem cell source has been published; the only related study is a recent report comparing unrelated bone marrow (BM) and UCB-SCT in Eastern adult patients with acute leukemia [23] .
We retrospectively analyzed the outcome of adult patients undergoing unrelated SCT for poorprognosis ALL in 13 transplantation centers in Spain between 2000 and 2007, focusing on the hematopoietic stem cell (HSC) source.
METHODS Patients
A total of 149 adult patients (median age, 29 years; range, 15-59 years) with poor-prognosis ALL underwent an unrelated SCT in 13 Spanish institutions between 2000 and 2007. ALL was of precursor B cell lineage in 111 patients (74%), of T cell lineage in 28 patients (19%), and of undetermined lineage in 10 patients (7%). ALL was in first CR (CR1) in 81 patients (54%), in second CR (CR2) in 37 patients (25%), in third CR (CR3) in 11 patients (7%), and with overt disease in 20 patients (13%). Patients were treated with PETHEMA ALL-93 trial [10] or PETHEMA ALL-AR03 trial [24] protocols. After 2003, 39 patients with Philadelphia chromosome-positive ALL were treated with the CSTIBES02 trial protocol and received imatinib in combination with chemotherapy and SCT [25] , with 25 undergoing UD-SCT and 14 undergoing UCB-SCT. The median time from diagnosis to SCT was 0.85 years (range, 0.08-16.48 years) for UD-SCT and 0.72 years (range, 0.06-11.10 years) for UCB-SCT. The hematopoietic progenitor source was a single unmanipulated UCB unit in 62 patients (41%), mobilized peripheral blood in 41 patients (28%), and unmodified BM in 46 patients (31%) ( Table 1) .
High-risk ALL was defined as in PETHEMA ALL-93 trial [10] . The criteria for indicating an unrelated SCT in CR1 was the presence of at least one of the following adverse prognostic factors: aged .30 years, white blood cell count (WBC) .30 Â 10 9 /L, adverse cytogenetics (t [9; 22] , t [4;11] or other 11q23 rearrangements, and t [1;19] ), or slow response to induction therapy (defined as .10% blasts in BM on day 15 of induction therapy).
SCT Procedure
Before 2004, UD selection was based on HLA serotyping performed for class I antigens (HLA-A and -B antigens) and high-resolution genotyping for class II antigens (HLA-DR), and required 5 or 6 of 6 identities. After 2004, the requirements included 7 or 8 of 8 allelic identities (HLA-A, -B, -C, and -DR). The requirements for UCB-SCT were 4-6 of 6 HLA-A/-B antigenic and -DR allelic identities.
Conditioning therapy consisted of total body irradiation (TBI) and cyclophosphamide (Cy) in 68 patients (46%), busulfan (Bu) and Cy in 9 patients (6%), thiotepa-Bu-Cy or fludarabine in 60 patients (40%; all of whom underwent UCB-SCT), and another regimen in 12 patients (8%) ( Table 2) .
Definitions of Outcomes
Leukocyte and platelet engraftment were defined as an absolute neutrophil count (ANC) .0.5 Â 10 9 /L in the first of 3 consecutive days and a platelet count .20 Â 10 9 /L in the first of 7 consecutive days without transfusion support, respectively. Graft failure was defined as the absence of neutrophil recovery at day 130 after UD-SCT or at day 160 after UCB-SCT. Patients with graft failure were censored for the assessment of graft-versus-host disease (GVHD). Acute graft-versus-host disease (aGVHD) was diagnosed and graded using standard criteria [26] and was assessed only in patients who achieved engraftment or survived for .30 days. Chronic GVHD (cGVHD) was assessed in patients who survived .100 days and was graded as limited or extensive according to classical criteria [27, 28] .
TRM was defined as any death related to the transplantation procedure and not to relapse. CR was considered as normal reconstitution of BM cellularity with \5% leukemic blasts and a neutrophil count .1.5 Â 10 9 /L together with a platelet count .100 Â 10 9 /L, along with the absence of any clinical evidence of leukemia. Relapse was defined as morphological evidence of leukemia in BM or other sites in a patient previously in CR. Overall survival (OS) was calculated from the time of transplantation to death from any cause, and disease-free survival (DFS) was defined as the time from transplantation to either first relapse or to death in CR. Only patients with a first allogeneic SCT were considered for the study; any patients who underwent a second transplantation because of nonengraftment of the first one were censored at the time of the second transplantation.
Statistical Analysis
The major endpoint of this study was to analyze OS and DFS in adult patients with high-risk ALL who underwent unrelated SCT with cord blood progenitors, BM, or mobilized peripheral blood progenitors. An analysis restricted to patients who underwent transplantation in CR1 was performed. Patient and disease characteristics were compared for categorical variables using the c 2 or Fisher's exact test and for continuous variables using bivariate tests (Student t test, Mann-Whitney U test, or analysis of variance as appropriate). Survival probabilities were estimated by the Kaplan-Meier method [29] and were compared with data from the log-rank test. Only the variables that were significantly different (P \ .05) or with borderline significance (P \ .15) in the univariate analysis were included in the Cox proportional hazard regression model. Cumulative incidence curves were used in a competing-risk setting to calculate the probability of relapse and TRM. For relapse, death without relapse was the competing event; for TRM, relapse was the competing event. The Gray test was used for group comparisons of cumulative incidence [30] . All statistical tests except cumulative incidence with competing risks (performed with R version 2.7.0; R Foundation for Statistical Computing) were performed using SPSS version 15.0 (SPSS, Chicago, IL).
RESULTS

Patients and Transplantation Procedures
Patients and transplantation characteristics are summarized in Tables 1 and 2 . No differences were found in terms of BM versus peripheral blood progenitors; thus, both sources of UD-SCT were considered together for comparison with UCB-SCT. Patients receiving UCB-SCT and UD-SCT were comparable for the main clinical and biological variables Table 1 . The UCB-SCT group included more patients with adverse cytogenetics (t[9;22] and t [4;11] ) and active disease (refractory and relapsed patients) ( Table 1 ). As expected, in the latter group of patients, HLA incompatibility was present in most cases, and the conditioning therapy (thiotepa-Bu-Cy or fludarabine and antithymocyte globulin [ATG]) differed from that used in the UD-SCT group ( 
Engraftment and Posttransplantation Complications
The time to hematologic recovery was longer and the frequency of graft failure was higher in the UCB-SCT group compared with the UD-SCT group (Table 3) . No difference in the incidence of bacterial, fungal, or viral infections was seen between the 2 groups. Ninety-two patients (63%) developed aGVHD grade I or higher, and 15 (17%) and 41 (47%) of 88 evaluable patients developed limited cGVHD and extensive cGVHD, respectively. No significant differences in the incidence of severe aGVHD (grades III-IV) or of limited or extensive cGVHD were seen between the UD-SCT and UCB-SCT groups ( Table 3 ). The incidences of hemorrhagic cystitis, microangiopathy, and hepatic obstructive sinusoidal syndrome were similar in the 2 groups.
TRM
Estimated TRM at 1 year was significantly lower in the UCB-SCT group (31% [19%-43%] vs 48% [36%-58%]; P 5 .023) ( Figure 1 ). The major causes of death differed in the 2 groups, with relapse or disease progression the main causes in the UCB-SCT group and GVHD and infection the main causes in the UD-SCT group (Table 3 ).
In the univariate analysis, factors predictive of a higher TRM were stem cell source (with a higher TRM in the UD-SCT group), WBC count at diagnosis .30 Â 10 9 /L, presence of severe aGVHD, and presence of extensive cGVHD. There was a trend toward a higher TRM for patients receiving TBI in the conditioning regimen (P 5 .058) and for patients aged .30 years (P 5 .069). In the multivariate analysis, only severe aGVHD was significantly associated with a higher risk of TRM (OR, 4.237; 95% CI, 2.232-8.00; P \ .001), however (Table 4) .
For those patients undergoing transplantation in CR1, a high WBC count at diagnosis, severe aGVHD, and extensive cGVHD were associated with higher risk of TRM in the univariate analysis. Only a leukocyte count at diagnosis .30 Â 10 9 /L was unequivocally associated with a high TRM in the multivariate analysis (Table 5 ).
Relapse Rate
The overall relapse rate was 15% (95% CI, 10%-20%) at 1 year, 22% (95% CI, 15%-29%) at 2 years, and 29% (95% CI, 20%-38%) at 5 years. There was no difference in the relapse probability in the UD-SCT and UCB-SCT groups, with a median time to relapse of 38.87 months (range, 16.43-61.30 months) for the UCB-SCT group and not achieved for the UD-SCT group. The factors influencing relapse rate in univariate analysis were TBI-containing conditioning, absence of ATG as GVHD prophylaxis, development of grade III-IV aGVHD, development of cGVHD, and disease status in CR1 (Table 4 ). In multivariate analyses, the only factors associated with lower relapse rate were disease status in CR1 and the development of cGVHD (Table 4 and figures 2A and B).
OS and DFS
The median follow-up after SCT was 20 months (range, 0.3-101.4 months) for the whole group, 23 Figure 1A ). For patients in CR1, the median OS was 12 months (95% CI, 0-29 months) for the whole group, 27 months (95% CI, 2-51) for UD-SCT, and 10 months (95 CI%, 0-23 months) for UCB-SCT. The estimated OS for the whole group was 47% (95% CI, 38%-56%) at 1 year, 40% (95% CI, 31%-49%) at 2 years, and 26% (95% CI, 17%-35%) at 5 years. The estimated 5-year OS was 22% (95% CI, 11%-33%) for UD-SCT and 33% (95% CI, 18%-48%) for UCB-SCT. On univariate analysis, factors associated with lower OS probability were WBC count .30 Â 10 9 /L at diagnosis (P 5 .028) and grade III-IV aGVHD (P \ .001); however, only the presence of severe aGVHD was associated with a poorer outcome on multivariate analysis (Table 4 ).
The median DFS was 7 months (95% CI, 3-11 months) for the whole group, 5 months (95% CI, 2-9 months) for UD-SCT, and 9 months (95% CI, 1-17 months) for UCB-SCT ( Figure 3B ). The estimated DFS for the whole group was 43% (95% CI, 34%-52%) at 1 year, 33% (95% CI, 24%-42%) at 2 years, and 21% (95% CI, 13%-29%) at 5 years. The estimated DFS at 5 years was 21% (95% CI, 11%-31%) for UD-SCT and 22% (95% CI, 8%-36%) for UCB-SCT. For patients in CR1, the median DFS was 12 months (95% CI, 2-22 months) for the whole group, 12 months (95% CI, 2-22 months) for UD-SCT, and 10 months (95% CI, 0-26 months) for UCB-SCT (P 5 NS). In univariate analysis, the sole factor associated with lower DFS probability was the presence of grade III-IV aGVHD (P \ .001), which was confirmed in multivariate analysis (OR, 3.876; 95% CI, 2.041-7.353; P \ . 001) ( Table 4) .
No significant differences in OS or DFS at 5 years were seen between the UCB-SCT and UD-SCT groups (Figure 1A and B) . Neither was any significant difference in OS and DFS detected between patients undergoing an 8/8 allele-matched UD-SCT and those undergoing a 4-6/6-matched UCB-SCT. In addition, no significant differences were observed in DFS or OS between the periods 2000-2003 and 2004-2007, or on comparison with centers reporting more versus fewer than 15 UD-SCTs (data not shown). For those patients undergoing transplantation in CR1, even though severe aGVHD and extensive cGVHD were associated with a worse DFS and OS, only a high leukocyte count was found to influence DFS in multivariate analysis ( Table 5) .
DISCUSSION
Our findings demonstrate that UCB-SCT and UCB-SCT are associated with high TRM and a poor long-term DFS and OS in poor-prognosis ALL adult patients without a sibling donor. Severe aGVHD was found to be the most important factor for OS, DFS, and TRM. In contrast, only disease status at the time of transplantation and the presence of cGVHD affected the relapse rate in this group of patients. Several previous studies have described outcomes of UCB-SCT and compared them with those of UD-SCT [19] [20] [21] 31] ; however, these studies included both acute myelogenous and lymphoid leukemias, and some included some proportion of pediatric patients. Moreover, OS, DFS, and TRM were usually estimated for short periods (1-3 years), leading to underestimation of late TRM.
Three major studies compared the outcomes of ALL after unrelated SCT, focusing on the HSC source. One of these studies was performed in pediatric patients, in whom CB is now a well-established stem cell source [32] . The second was a large study of Japanese adults with acute leukemia involving a disease-specific comparison [23] . In that study, mobilized peripheral blood was not used as a stem cell source, and BM was always 8/8 genotypically matched. In the ALL group, no differences in TRM, OS, or DFS were seen in patients receiving BM or UCB as the stem cell source; there was only a trend for a higher cumulative incidence of relapse and a significant lower incidence of cGVHD and aGVHD in the UCB recipients. The University of Minnesota group reported their longterm experience with TBI-based myeloablative SCT in adult and pediatric patients with ALL [33] , noting poor outcomes with autologous SCT and similar outcomes for related donor, UD, and UCB SCT [33] .
To the best of our knowledge, our study is the largest published report in Western adult patients with high-risk ALL receiving unrelated hematopoietic progenitors for SCT. Our findings indicate that the stem cell source was not relevant to patient outcome. Although we found a lower TRM in patients receiving a UCB-SCT, this did not translate to a better OS or DFS. As in previous reports, the patients undergoing UCB-SCT had worse prognostic factors than those undergoing UD-SCT (ie, more advanced disease status at transplantation and a higher prevalence of t[9;22] rearrangement). Although some previous data have pointed toward a worse prognosis in patients receiving mobilized peripheral blood compared with those receiving BM in the unrelated setting for ALL [34] , we detected no such difference in our study.
One relevant finding in the present study is the low expected long-term survival (when considered at 5 years). But this study included a very-high-risk ALL population, in whom TRM and relapse rate turned out to be higher than those for patients who underwent allogeneic SCT for acute myelogenous leukemia [23] . Moreover, the long follow-up allowed observation of late events (ie, relapse or death related to cGVHD) that decreased the life expectancy in these patients. Moreover, even if some authors might consider .100 Â 10 9 lymphoblasts/L, but .30 Â 10 9 lymphoblasts/L as an adverse prognostic factor in patients with ALL of T cell ineage, none of the patients in this study presented with this adverse prognostic factor.
In contrast to other reports [35] , we found no significant impact of HLA mismatch on OS or DFS in the UD-SCT group (data not shown). This might because of the limited number of patients undergoing UD-SCT in this study, however. Moreover, we found no difference in survival between patients undergoing an 8/8-matched UD-SCT and those undergoing a 4-6/ 6-matched UCB-SCT.
For patients undergoing SCT in CR1, a high WBC count at diagnosis was the strongest predictor of survival in multivariate analysis. For such patients, the presence of aGVHD and cGVHD influenced survival and TRM in univariate analysis. However, unlike in the whole series, this was not confirmed in multivariate analysis, probably because of the small number of patients analyzed.
The main limitations of the present study are related to its retrospective nature. Only a study randomizing UCB-SCT and UD-SCT could unequivocally answer the question of the best hematopoietic progenitor source for unrelated SCT in adult ALL patients; however, such a study would be very difficult or almost impossible to perform in patients with a suitable UD and suitable unrelated UCB units. We restricted our study to the period 2000-2007. Since 2004, highresolution HLA class I and II determination has been common practice in UD searches in Spain; thus, we compared the outcomes between the periods 2000-2003 and 2004-2007 , and found them to be similar. The second limitation is the study's multicenter setting, with possible heterogeneity in the high-risk criteria used to evaluate patients' suitability for alternative-donor SCT. An exhaustive review of the inclusion criteria for this study found that most of the patients fulfilled more than one of these criteria. The third study limitation is related to the impossibility of studying the impact of cGVHD on TRM, relapse rate, or survival with the newly defined National Institutes of Health standards [36] , given the study's multicenter and retrospective nature. Applied in future prospective studies, these standards will be more accurate in evaluating cGVHD after each modality of unrelated SCT. Finally, in cases with more than one option (UD or UCB), we cannot know which criteria were used in each institution to select one source or the other. However, in many centers even today, a reasonably matched UD (8-10/10) is preferred to UCB (which is inevitably mismatched in most cases).
Despite the well-known delayed immune reconstitution and greater infectious vulnerability after UCB-SCT [18, 37, 38] , the incidence of infectious episodes in our study was similar in the UCB-SCT and UD-SCT groups. The incidence of death attributed exclusively to infection (not associated with the presence of GVHD) also was similar in the 2 groups. The main cause of death was disease relapse in the UCB-SCT group and GVHD in the UD-SCT group.
The incidence of severe aGVHD found in our study is higher than that reported by previous studies of unrelated SCT [11, 13, 39, 40] , especially when the source of stem cells was unrelated peripheral blood or BM. The high incidence of HLA mismatch in our series, the absence of ATG in the conditioning therapy in most patients, and, finally, the genetic heterogeneity in the Spanish population (in contrast to the Scandinavian or Japanese population) may be responsible for this difference in GVHD rate. The antileukemic activity of GVHD traditionally has been considered weaker in ALL than in other hematologic diseases; however, many authors [11, [41] [42] [43] [44] have shown the antileukemic effect of cGVHD, especially the limited type, in adult patients undergoing both related and unrelated allogeneic SCT. In our study, the presence of cGVHD and ALL status at transplantation were the strongest factors influencing relapse, similar to what has been reported in the related transplantation setting [2, 6, 40, 45, 46] . Even if the presence of cGVHD protected against relapse in our study, it had no significant impact on OS or DFS, probably because of the numerous factors that interfere with survival in the unrelated transplantation setting. The graftversus-leukemia effect of cGVHD has been found to be stronger in patients with translocations (including Philadelphia chromosome-positive ALL) [44] or with normal diploid cytogenetics than in patients with deletions or numeric abnormalities [41] . We could not prove such an effect in this group of patients in our study, however (data not shown). As expected, the presence of severe aGVHD had a strong adverse effect on patient outcome; however, it had a positive impact on decreasing the relapse rate, as has been reported previously [13, 14] . This effect might become more advantageous if we could reduce the nonrelapse mortality associated with severe aGVHD.
Conditioning regimens that include TBI have been associated with improved DFS in ALL patients undergoing autologous or allogeneic SCT [47] . Our exploration of the particular effect of TBI on the relapse rate of the whole group revealed a trend toward a higher relapse rate in the patients who did not receive TBI. But these patients were mostly recipients of UCB progenitors, who had a significantly lower rate of cGVHD, which was one of the most important factors in preventing relapse in multivariate analysis. The use of ATG in all UCB-SCT recipients also could have contributed to the higher relapse rate in this group. When examining the impact of TBI in the UD-SCT group, we found no influence on relapse rate. Disease status at the time of transplantation and the presence of cGVHD were the main factors influencing relapse in adult patients with high-risk ALL after an unrelated SCT. The lower incidence of GVHD seen in the UCB-SCT group could explain the trend toward a higher relapse rate in these patients.
Previously explored strategies to reduce TRM in UCB-SCT have included reduced-intensity conditioning, double or multiple grafts [15, 37, 48] , third-party infusions [21] , and intrabone UCB administration [49, 50] . In the present study, all patients in the UCB-SCT group received a single UCB graft with standard administration techniques. In the UD-SCT setting, generalized high-resolution typing methods [51] and more efficient transmission of data by the donor registries should improve the clinical outcome in patients with a high-risk ALL without a sibling donor. Improvements are also needed in the management and modulation of GVHD and prevention of relapse in these patients.
In conclusion, based on our results, UCB or UD hematopoietic progenitors should be indiscriminately considered for unrelated transplantation in poor-risk adult ALL patients without a sibling donor. Factors influencing relapse are similar to those observed in SCT from HLA-identical siblings. This study supports the unrestricted use of either HSC source in adult patients with high-risk ALL without a histocompatible related donor. Financial disclosure: This work was supported by grants from the Jose Carreras Leukaemia Foundation (PEF-08) and RETIC, Instituto Carlos III (RD 06/ 0020/1056). The authors have not any conflict of interest to declare.
